Tatiana Ivanovna Ishina

Dr. Tatiana Ivanovna Ishina

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
VPV I Podzolkov
V I Podzolkov
GMG K Makhnach
G K Makhnach
TITatiana Ivanovna Ishina
Tatiana Ivanovna Ishina
APA B Ponomarev
A B Ponomarev
IMIvan Medvedev
Ivan Medvedev
The article analyzes the diagnosis and treatment of anti-GBM antibody disease (Goodpasture's syndrome) – a rare, severe progressive disease, associated with anti-glomerular basement membrane antibody-induced pulmonary hemorrhage and glomerulonephritis. The main problem of this pathology is late diagnosis, resulted in ineffective treatment. The article provides current information on the epidemiology, etiology and pathogenesis, diagnosis, and treatment of Goodpasture’s syndrome, as well as clinical case of a patient with this rare disease. Keywords: anti-GBM antibody disease, Goodpasture's syndrome, pulmonary-renal syndrome, rapidly progressive glomerulonephritis

29 September 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
VPV I Podzolkov
V I Podzolkov
MVM V Vetluzhskaya
M V Vetluzhskaya
AAA A Abramova
A A Abramova
TITatiana Ivanovna Ishina
Tatiana Ivanovna Ishina
KGK I Garifullina
K I Garifullina
Vaping, i.e. the use of electronic nicotine/other substances delivery systems, increases a risk of vaping-associated lung injury. The review describes clinical manifestation, methods of diagnosis and diagnostic criteria, treatment of patients with this disease as well as risk stratification of vapers and approaches to their management based on Worchester classification and clinical guidance. The pathogenetic mechanisms of vaping-associated lung injury have been analyzed.

21 December 2018 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
VPV. I. Podzolkov
V. I. Podzolkov
ABAnna E. Bragina
Anna E. Bragina
TITatiana Ivanovna Ishina
Tatiana Ivanovna Ishina
LBL. V. Bragina
L. V. Bragina
LVL. V. Vasilyeva
L. V. Vasilyeva
The current population is characterized by a high prevalence of risk factors for the development of chronic kidney disease: hypertension, diabetes, obesity, metabolic syndrome, physical inactivity, smoking. The development of severe complications and a close connection with potentially fatal cardiovascular disorders make this disease a socially and economically significant problem. Treatment of chronic kidney disease in advanced stages belong to nephrologist duties. However, the success of preventive interventions depends on the time of their onset, which makes it relevant to identify the disease. The use of nephroprotective approaches by physicians of different specialties (general practitioners, cardiologists, gerontologists, nephrologists, endocrinologists) can significantly improve the prognosis of both those at risk of developing renal dysfunction and the existing disease. The review presents data on the clinical and laboratory efficacy of angiotensin-renin blocker use, as well as the combination of angiotensin II receptor blockers with calcium antagonists. Using the combination of the angiotensin II receptor blocker irbesartan and amlodipine as an example, we demonstrated the possibilities of nephroprotective therapy in patients with renal dysfunction.

22 January 2024 in Current Hypertension Reviews
Verified
Journal Article
Open access
PDF file
VPValery Podzolkov
Valery Podzolkov
ABAnna E. Bragina
Anna E. Bragina
ATAida Tarzimanova
Aida Tarzimanova
LVLyubov Vasilyeva
Lyubov Vasilyeva
ISIlya Shvedov
Ilya Shvedov
ACAlexander Cherepanov
Alexander Cherepanov
Background: COVID-19 is characterized by an acute inflammatory response with the formation of endothelial dysfunction and may affect arterial stiffness. Studies of cardio-ankle vascular index in COVID-19 patients with considered cardiovascular risk factors have not been conducted. Objective: The purpose of our study was to assess the association between cardio-ankle vascular index and COVID-19 in hospitalized patients adjusted for known cardiovascular risk factors. Methods: A cross-sectional study included 174 people hospitalized with a diagnosis of moderate COVID-19 and 94 people without COVID-19. Significant differences in the cardio-ankle vascular index values measured by VaSera VS - 1500N between the two groups were analyzed using parametric (Student's t-criterion) and nonparametric (Mann-Whitney) criteria. Independent association between COVID-19 and an increased cardio-ankle vascular index ≥ 9.0 adjusted for known cardiovascular risk factors was assessed by multivariate logistic regression. Results: There were significantly higher values of the right cardio-ankle vascular index 8.10 [7.00;9.40] and the left cardio-ankle vascular index 8.10 [6.95;9.65] in patients undergoing inpatient treatment for COVID-19 than in the control group – 7.55 [6.60;8.60] and 7.60 [6.60;8.70], respectively. A multivariate logistic regression model adjusted for age, hypertension, plasma glucose level, glomerular filtration rate and diabetes mellitus showed a significant association between increased cardio-ankle vascular index and COVID-19 (OR 2.41 [CI 1.09;5.30]). Conclusion: Hospitalized patients with COVID-19 had significantly higher cardio-ankle vascular index values compared to the control group. An association between an increased cardio-ankle vascular index and COVID-19 was revealed, independent of age, hypertension, plasma glucose level, glomerular filtration rate and diabetes mellitus.

7 July 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
VPV. I. Podzolkov
V. I. Podzolkov
TITatiana Ivanovna Ishina
Tatiana Ivanovna Ishina
IMIvan Medvedev
Ivan Medvedev
MVM. V. Vetluzhskaya
M. V. Vetluzhskaya
NDN. A. Dragomiretskaya
N. A. Dragomiretskaya
AYA. S. Yasneva
A. S. Yasneva
Coronavirus disease 2019 (COVID-19) is a disease characterized by diverse clinical manifestations, the severity of which can vary from asymptomatic to extremely severe. At this stage, the urgent task is the early detection of reliable markers of its severity in the acute period of infection and possible changes that cause symptoms in the post-COVID period. The severe COVID-19 is associated with extensive damage to the lungs, pulmonary vessels, and cardiovascular system. In this regard, it seems natural to study the problem of pulmonary hypertension (PH) and right ventricular dysfunction (RVD) in patients with COVID-19, and their significance for assessing the severity of the condition and prognosis. Also important is the availability of reliable non-invasive diagnostics. This review presents data on the incidence of PH and RVD and their potential significance in patients with COVID-19. We have analyzed literature sources in the eLIBRARY, PubMed/MEDLINE, ScienceDirect and ProQuest databases.

1 August 2024 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
ABAnna E. Bragina
Anna E. Bragina
ATAida I. Tarzimanova
Aida I. Tarzimanova
YRYulia N. Rodionova
Yulia N. Rodionova
EOEkaterina S. Ogibenina
Ekaterina S. Ogibenina
ASAleksandr Suvorov
Aleksandr Suvorov
VPValery I. Podzolkov
Valery I. Podzolkov
Background: Different variants of single nucleotide polymorphisms (SNPs) of angiotensinogen (AGT), angiotensin-converting enzyme type 1 (ACE1), and angiotensin II receptors type 1 (AGTR1) and 2 (AGTR2) genes determine different susceptibility to cardiovascular disease (CVD) and hypertension, which can be considered as risk factors for fatal outcomes among coronavirus disease 2019 (COVID-19) patients. The objective of our study was to assess the relation between the frequency of SNPs of the renin-angiotensin system (RAS) components, and the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods: The cross-sectional study included 100 patients with a laboratory-confirmed diagnosis of COVID-19 admitted to the hospital. Criteria for severe COVID-19 included respiratory rate (RR) > 30/min, blood oxygen saturation (SpO2) ≤ 93%, signs of unstable hemodynamics with systolic blood pressure (SBP) < 90 and/or diastolic blood pressure (DBP) < 60 mm Hg. All patients were identified with alleles and genotypes of the polymorphic markers rs4762 of the AGT gene, rs1799752 of the ACE1 gene, rs5186 of the AGTR1 gene and rs1403543 of the AGTR2 gene using the polymerase chain reaction method in human DNA preparations on real-time CFX96C1000 Touch, Bio-Rad equipment (Syntol, Russia). Statistical analysis was performed in R v.4.2. Results: Patients were divided into groups with severe (n = 44) and moderate COVID-19 (n = 56). For ACE1 rs1799752, a significant deviation from the population distribution was detected in both studied subgroups. A higher frequency of the C allele SNP rs5186 AGTR1 gene was detected in the group with severe disease. More frequent A/A genotype of SNP rs1403543 AGTR2 was detected among females with severe COVID-19. Haplotype analysis revealed more common DCG haplotype among patients with severe COVID-19. The odds ratio for severe COVID-19 in the presence of the DCG haplotype was 3.996 (95% confidential interval: 1.080 -14.791, P < 0.05). Conclusions: Our data suggest that the SNP genes of the RAS components, may allow to identify groups of patients predisposed to a more severe course of COVID-19.